Articles producció científica> Medicina i Cirurgia

New perspectives on CKD-induced dyslipidemia

  • Identification data

    Identifier: imarina:5251825
    Authors:
    Bermúdez-López M., Arroyo D., Betriu À., Masana L., Fernández E., Valdivielso J.
    Abstract:
    Introduction: Chronic kidney disease (CKD) is a world-wide health concern associated with a significantly higher cardiovascular morbidity and mortality. One of the principal cardiovascular risk factors is the lipid profile. CKD patients have a more frequent and progressive atheromatous disease that cannot be explained by the classical lipid parameters used in the daily clinical practice. Areas covered: The current review summarizes prevailing knowledge on the role of lipids in atheromathosis in CKD patients, including an overview of lipoprotein metabolism highlighting the CKD-induced alterations. Moreover, to obtain information beyond traditional lipid parameters, new state-of-the-art technologies such as lipoprotein subfraction profiling and lipidomics are also reviewed. Finally, we analyse the potential of new lipoprotein subclasses as therapeutic targets in CKD. Expert opinion: The CKD-induced lipid profile has specific features distinct from the general population. Besides quantitative alterations, renal patients have a plethora of qualitative lipid alterations that cannot be detected by routine determinations and are responsible for the excess of cardiovascular risk. New parameters, such as lipoprotein particle number and size, together with new biomarkers obtained by lipidomics will personalize the management of these patients. Therefore, nephrologists need to be aware of new insights into lipoprotein metabolism to improve cardiovascular risk assessment.
  • Others:

    Author, as appears in the article.: Bermúdez-López M., Arroyo D., Betriu À., Masana L., Fernández E., Valdivielso J.
    Department: Medicina i Cirurgia
    URV's Author/s: Masana Marín, Luis
    Keywords: Type-2 diabetes-mellitus Subclinical atheromatosis Risk-factors Peritoneal-dialysis Lipoproteins Lipid abnormalities High-density-lipoprotein Hemodialysis-patients Dyslipidemia Chronic-renal-failure Chronic kidney-disease Chronic kidney disease Cardiovascular-disease Cardiovascular disease Atherosclerosis dyslipidemia chronic kidney disease cardiovascular disease atherosclerosis
    Abstract: Introduction: Chronic kidney disease (CKD) is a world-wide health concern associated with a significantly higher cardiovascular morbidity and mortality. One of the principal cardiovascular risk factors is the lipid profile. CKD patients have a more frequent and progressive atheromatous disease that cannot be explained by the classical lipid parameters used in the daily clinical practice. Areas covered: The current review summarizes prevailing knowledge on the role of lipids in atheromathosis in CKD patients, including an overview of lipoprotein metabolism highlighting the CKD-induced alterations. Moreover, to obtain information beyond traditional lipid parameters, new state-of-the-art technologies such as lipoprotein subfraction profiling and lipidomics are also reviewed. Finally, we analyse the potential of new lipoprotein subclasses as therapeutic targets in CKD. Expert opinion: The CKD-induced lipid profile has specific features distinct from the general population. Besides quantitative alterations, renal patients have a plethora of qualitative lipid alterations that cannot be detected by routine determinations and are responsible for the excess of cardiovascular risk. New parameters, such as lipoprotein particle number and size, together with new biomarkers obtained by lipidomics will personalize the management of these patients. Therefore, nephrologists need to be aware of new insights into lipoprotein metabolism to improve cardiovascular risk assessment.
    Thematic Areas: Pharmacology & pharmacy Pharmacology Molecular medicine Medicina ii Medicina i Interdisciplinar Farmacia Ensino Drug discovery Clinical biochemistry Ciências biológicas iii Ciências biológicas ii Ciência de alimentos
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 14728222
    Author's mail: luis.masana@urv.cat
    Author identifier: 0000-0002-0789-4954
    Record's date: 2024-09-07
    Papper version: info:eu-repo/semantics/acceptedVersion
    Link to the original source: https://www.tandfonline.com/doi/abs/10.1080/14728222.2017.1369961?journalCode=iett20
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Expert Opinion On Therapeutic Targets. 21 (10): 967-976
    APA: Bermúdez-López M., Arroyo D., Betriu À., Masana L., Fernández E., Valdivielso J. (2017). New perspectives on CKD-induced dyslipidemia. Expert Opinion On Therapeutic Targets, 21(10), 967-976. DOI: 10.1080/14728222.2017.1369961
    Article's DOI: 10.1080/14728222.2017.1369961
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2017
    Publication Type: Journal Publications
  • Keywords:

    Clinical Biochemistry,Drug Discovery,Molecular Medicine,Pharmacology,Pharmacology & Pharmacy
    Type-2 diabetes-mellitus
    Subclinical atheromatosis
    Risk-factors
    Peritoneal-dialysis
    Lipoproteins
    Lipid abnormalities
    High-density-lipoprotein
    Hemodialysis-patients
    Dyslipidemia
    Chronic-renal-failure
    Chronic kidney-disease
    Chronic kidney disease
    Cardiovascular-disease
    Cardiovascular disease
    Atherosclerosis
    dyslipidemia
    chronic kidney disease
    cardiovascular disease
    atherosclerosis
    Pharmacology & pharmacy
    Pharmacology
    Molecular medicine
    Medicina ii
    Medicina i
    Interdisciplinar
    Farmacia
    Ensino
    Drug discovery
    Clinical biochemistry
    Ciências biológicas iii
    Ciências biológicas ii
    Ciência de alimentos
  • Documents:

  • Cerca a google

    Search to google scholar